Comprehensive immune cell profiling depicts an early immune response associated with severe coronavirus disease 2019 in cancer patients. Issue 1 (27th October 2021)

• Record Type: Journal Article
• Authors: Tembhare, Prashant R; Sriram, Harshini; Chatterjee, Gaurav; Khanka, Twinkle; Gokarn, Anant; Mirgh, Sumeet; Rajendra, Akhil; Chaturvedi, Anumeha; Ghogale, Sitaram G; Deshpande, Nilesh; Girase, Karishma; Dalvi, Kajal; Rajpal, Sweta; Patkar, Nikhil; Trivedi, Bhakti; Joshi, Amit; Murthy, Vedang; Shetty, Nitin; Nair, Sudhir; More, Ashwini; Kamtalwar, Sujeet; Chavan, Preeti; Bhat, Vivek; Bhat, Prashant; Subramanian, Papagudi G; Gupta, Sudeep; Khattry, Navin
• Is Part Of: Immunology and cell biology. Volume 100:Issue 1(2022)
• Page Start: 61
• Page End: 73
• Publication Date: 2021-10-27
• Subjects: Cancer patients -- COVID‐19 -- immune cell profile -- inflammatory cytokines -- myeloid dendritic cells -- SARS‐CoV‐2 -- severe disease; Immunology -- Periodicals; Cytology -- Periodicals; 616.079
• DOI: 10.1111/imcb.12504
• Languages: English
• ISSNs: 0818-9641

Abstract

Abstract: Recent studies have highlighted multiple immune perturbations related to severe acute respiratory syndrome coronavirus 2 infection–associated respiratory disease [coronavirus disease 2019 (COVID‐19)]. Some of them were associated with immunopathogenesis of severe COVID‐19. However, reports on immunological indicators of severe COVID‐19 in the early phase of infection in patients with comorbidities such as cancer are scarce. We prospectively studied about 200 immune response parameters, including a comprehensive immune‐cell profile, inflammatory cytokines and other parameters, in 95 patients with COVID‐19 (37 cancer patients without active disease and intensive chemo/immunotherapy, 58 patients without cancer) and 21 healthy donors. Of 95 patients, 41 had severe disease, and the remaining 54 were categorized as having a nonsevere disease. We evaluated the association of immune response parameters with severe COVID‐19. By principal component analysis, three immune signatures defining characteristic immune responses in COVID‐19 patients were found. Immune cell perturbations, in particular, decreased levels of circulating dendritic cells (DCs) along with reduced levels of CD4 T‐cell subsets such as regulatory T cells (Tregs ), type 1 T helper (Th1) and Th9; additionally, relative expansion of effector natural killer (NK) cells were significantly associated with severe COVID‐19. Compared with patients without cancer, the levels of terminal effector CD4 T cells, Tregs, Th9, effector NK cells, B cells, intermediate‐type monocytes and myeloid DCs were significantly lower in cancer patients with mild and severe COVID‐19. We concluded that severely depleted circulating myeloid DCs and helper T subsets in the initial phase of infection were strongly associated with severe COVID‐19 independent of age, type of comorbidity and other parameters. Thus, our study describes the early immune response associated with severe COVID‐19 in cancer patients without intensive chemo/immunotherapy. Abstract : We studied an early immune response in COVID‐19 in patients with cancer. We observed three distinct immune signatures defining characteristic immune response in COVID‐19 patients. Our data highlight that reduced levels of circulating helper T cells and dendritic cells in the early phase of infection were significantly associated with progression to severe disease. Severely depleted levels of circulating conventional dendritic cells were independently associated with severe COVID‐19 in patients with cancer.